Photopharmacological Agents in the Management of Dementia of Alzheimer’s Disease and Other Aetiologies

Dementia types such as Alzheimer’s disease (AD), frontotemporal dementia, vascular dementia, and Lewy body dementia are multifactorial progressive diseases with loss of neurons and progressive cognitive deterioration. Conventional pharmacotherapies, despite decades of research, typically lack the ability to impact disease-defining outcomes in part because of suboptimal blood-brain barrier penetration, off-target effects, and the inability to exert spatiotemporal control. A new field in medicinal chemistry, called photopharmacology, aims to bypass these problems using photoswitchable molecules to switch their biological activity to a predetermined level with specific wavelengths of light. They are typically azobenzene, spiropyran, or diarylethene-based reversible activation or inhibition of target proteins, including ion channels, G-protein-coupled receptors, and enzymes related to neurodegeneration. Photopharmacological interventions have demonstrated possibilities to alter cholinergic transmission, effectively inhibit beta-secretase, cripple amyloid-beta assembly, and downregulate tau hyperphosphorylation in the context of Alzheimer’s disease, therefore targeting the fundamental pathological process. Similarly, with other patterns of dementia, there may be opportunities to modulate neurotransmitter systems under light control (e.g., dopaminergic and glutamatergic), which may enable recovery of a synaptic homeostasis without global inhibition of neurons. The possibility of deep-brain phototherapeutic interventions has also increased in recent years after the integration of nanotechnology and fiber-optic or near-infrared light delivery systems. In addition, temporal precision is possible with photopharmacology, thus providing on-demand therapy whereby systemic exposure is reduced, which minimizes the risk of adverse effects. Although promising, clinical translation of the technology is hampered by limitations in the penetration of light by human brain tissue, phototoxicity, in vivo stability of photo switches, and the creation of implantable light-transmission devices. Ongoing research into red-shifted and two-photon activatable switches, biodegradable light guides, and non-invasive wearable devices is paving the way for broader application in neurodegenerative disease management. This abstract underscores photopharmacology as a transformative strategy in dementia therapy, capable of reshaping the therapeutic landscape by offering reversible, localized, and temporally controlled interventions. With continued interdisciplinary collaboration across chemistry, neuroscience, optics, and bioengineering, photopharmacological therapeutics may soon transition from conceptual promise to clinical reality in managing AD and related dementias.